Australia · Delayed Price · Currency is AUD EBR Systems Earnings Call Transcripts
Fiscal Year 2026
-
Two key proposals were presented: a reverse stock split at a flexible ratio and ratification of securities issued in May 2025. Voting was conducted by poll, with results to be published on the ASX and company website.
-
The meeting focused on a proposal to consolidate common shares, freeing up authorized shares for future financing and strategic flexibility. Shareholders were assured that CDI holdings and value would not be affected, and no immediate plans for capital raising or U.S. listing were disclosed.
-
A unique leadless pacemaker for left ventricular pacing has launched with FDA approval and strong reimbursement, targeting a $5.8B U.S. market. Early adoption is on track, with modular compatibility enabling new therapies and a disciplined commercial rollout supporting growth.
Fiscal Year 2025
-
FDA approval and commercial rollout of leadless left ventricular pacing drove strong Q4 growth, with revenue over $900,000 and patient volume doubling sequentially. High physician engagement, robust reimbursement, and no direct competitors support continued expansion, while a new manufacturing facility and vertical integration are underway.
-
The meeting highlighted a pivotal year marked by FDA approval, commercial readiness, and strategic expansion plans. Shareholders voted on director reelections, equity plans, and option grants, with results to be published. Financial statements and audit matters were also addressed.